Pharmacopeia Earns Milestone Payment From Schering Plough On Initiation Of Phase 1 Clinical Trials Of Novel Therapeutic Candidate

Pharmacopeia (Nasdaq: PCOP), an innovator in the discovery and development of novel small molecule therapeutics, announced that Schering Plough has initiated a Phase 1 clinical trial in the United States with PS948115, a compound identified from the collaboration between the two companies. The compound is being evaluated as a potential treatment for respiratory disease. [click link for full article]

More: continued here

Filed under: Clinical Trials on September 26th, 2007